Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years'...

Area of Science:

• Oncology
• Radiation Oncology
• Thoracic Oncology

Background:

• Continuous hyperfractionated accelerated radiotherapy (CHART) is an established treatment option for non-small cell lung cancer (NSCLC).
• Previous UK experience with CHART treatment outcomes from 1998-2003 has been published.
• This study updates the UK CHART experience, focusing on patients treated between 2003 and 2009.

Purpose of the Study:

• To report updated treatment outcomes and toxicities for NSCLC patients treated with CHART from 2003 to 2009.
• To evaluate the effectiveness and safety of CHART in a real-world clinical setting.
• To compare current outcomes with the original CHART trial cohort.

Main Methods:

• Retrospective data analysis of NSCLC patients treated with CHART between 2003 and 2009.
• Data collected from nine participating UK CHART centers.
• Kaplan-Meier method used for survival estimation; Log-rank test for significance analysis.

Main Results:

• 849 patients received CHART treatment; median overall survival was 22 months (2-year survival 47%, 3-year survival 32%).
• Significant survival differences observed between stages IA vs. IB and IIIA vs. IIIB.
• Complete response at 3 months strongly correlated with improved survival (34 months).
• Age, gender, performance status, prior chemotherapy, and PET-CT did not significantly impact survival.
• Treatment was well-tolerated, with less than 5% reporting Grade 3 or higher toxicity.

Conclusions:

• CHART treatment for NSCLC in routine practice yields encouraging results with improved survival compared to the original trial.
• The study confirms CHART is a deliverable treatment with low toxicity rates.
• A dose-escalated CHART regimen is being advanced for a randomized phase II study.